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ABSTRACT There have been exponential  gains in immuno-oncology in recent times through the development of immune checkpoint
inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small cell lung cancer,
immune checkpoint inhibitors also appears to have significant antitumor activity in multiple other tumor types. An exciting
component of immunotherapy is the durability of antitumor responses observed, with some patients achieving disease control for
many years. Nevertheless, not all patients benefit, and efforts should thus now focus on improving the efficacy of immunotherapy
through the use of combination approaches and predictive biomarkers of response and resistance. There are multiple potential
rational combinations using an immunotherapy backbone, including existing treatments such as radiotherapy, chemotherapy or
molecularly targeted agents, as well as other immunotherapeutics. The aim of such antitumor strategies will be to raise the tail on
the survival curve by increasing the number of long term survivors, while managing any additive or synergistic toxicities that may
arise with immunotherapy combinations. Rational trial designs based on a clear understanding of tumor biology and drug
pharmacology remain paramount. This article reviews the biology underpinning immuno-oncology, discusses existing and novel
immunotherapeutic combinations currently in development, the challenges of predictive biomarkers of response and resistance
and the impact of immuno-oncology on early phase clinical trial design.
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Introduction
Immunotherapy has been utilized as a strategy for treating
cancer for over 100 years since the use of Coley’s toxins for
the  treatment  of  sarcoma1.  For  many  years,  the  focus  of
immunotherapy has been activation of the immune response
either through antitumor vaccines or direct stimulation with
interleukin-2  (IL-2)  or  interferon.  These  approaches
provided incontrovertible evidence that the immune system
could be harnessed to fight cancer, however responses have
been few and far between, although often durable when they
did  occur.  It  has  only  been  through  further  study  of  the
mechanistic  basis  of  the  immune  system  that  recent
breakthroughs have come, most notably through checkpoint
inhibition2.  By providing durable responses, partly due to
memory immune responses, immunotherapy has shifted the
focus of new treatments from the slope of the survival curve
[e.g.  median  overall  survival  (OS)  and  progression  free
survival (PFS)] to the tail of the survival curve (e.g. 2- or 5-
year survival rates)3,4.
There remains however, significant scope for increasing
the effectiveness of immunotherapy and in doing so raising
the tail  of  the curve.  For example,  combination strategies
with immunotherapy have great potential to be able to do
this by combining different but synergistic immunotherapies
or the pairing of immunotherapy with other modalities of
antitumor treatments, such as chemotherapies, molecularly
targeted  therapies  and  radiotherapy.  Early  phase  trials,
carefully  designed with  a  thorough understanding  of  the
underlying mechanisms involved in both therapeutics and
cancer  biology,  are  critical  for  the  safe  and  rational
development  of  combination  regimens  involving
immunotherapeutics.  In  this  review,  we  will  discuss  the
biology underpinning immunotherapy and detail key clinical
immuno-oncology advances. We will also focus on strategies
combining  existing  immunotherapy  with  chemotherapy,
radiotherapy,  molecularly  targeted  agents  and  novel
immunotherapeutics,  as  well  as  the  challenges  and
implications for early phase trial design.
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Immune surveillance, editing and
suppression
The underlying theory behind immune surveillance is that
many tumors are eliminated by the immune system, while
some cancers develop ways and means to escape the immune
response5.  A  clinically  apparent  tumor  is  one  that,  even
under the pressure of the immune system, has escaped from
immune recognition6,7.
The  two  main  pathways  in  which  tumors  escape  the
immune response include 'immuno-editing' whereby tumor
variants resistant to immune effectors are selected, with the
progressive  formation  of  an  immune  suppressive
environment within the tumor8-11. During cancer immuno-
editing, the host immune system shapes tumor fate in three
phases through the activation of innate and adaptive immune
mechanisms, namely elimination, equilibrium and escape9,10.
Genetic mouse models have shown that T cell recognition of
tumor  antigens  drives  the  adaptive  immunological
elimination, or 'sculpting' of a developing cancer12,13. It has
become recognized that interferons play an important role in
coordinating tumor-innate immune system interactions14,15.
Much work has focussed on the development of the tumor
immunosuppressive microenvironment, and the emergence
of T cell tolerance (Figures 1 and 2)16. The local interaction
between the immunologic milieu of dendritic cells (DCs),
myeloid  derived  suppressor  cells  (MDSCs),  regulatory  T
(Treg)  cells,  stromal  cells  and  T  cells  is  crucial  to  the
induction  of  tolerance.  Often  it  is  the  development  of
inhibitory  processes,  and  in  particular  expression  of
inhibitory pathways via co-inhibitory pathways or immune
checkpoints  that  inhibit  T cell  responses.  This  ultimately
leads  to  T  cell  exhaustion,  which  is  a  state  of  T  cell
dysfunction that arises in many cancers17,18. It is defined by
poor effector function, sustained expression of inhibitory
receptors and a transcriptional  state distinct  from that of
functional effector or memory T cells19. Importantly, T cell
exhaustion prevents the optimal control of tumors.
Key negative regulatory pathways or 'checkpoints' control
auto-reactivity  and  the  improved  understanding  of  their
involvement  in  cancer  has  revolutionized  tumor
immunotherapy20.  Cytotoxic  T  lymphocyte  antigen  4
(CTLA4)  is  expressed  mainly  on  the  surface  of  activated
CD4+  T  cells  and  Treg  cells,  and  plays  a  central  role  in
maintaining  immune  tolerance  by  inhibiting  T  cell  co-
stimulation21.  Programmed cell  death 1 (PD-1) is  mainly
expressed on activated T cells upon T cell receptor (TCR)
engagement and on Treg cells, and also identifies exhausted T
cells22. When bound to its ligand, programmed cell death 1
l igand  (PD-L1)  expressed  on  tumor  ce l l s ,  PD-1
downregulates T cell activity and leads to T cell exhaustion.
Thus, the rationale for targeting this checkpoint in cancer
therapy  is  to  release  the  'brakes'  on  pre-existing  tumor-
reactive T cells and to generate new T cell responses23. These
novel agents have revolutionized the treatment of cancer and
have led to impressive clinical benefits across a number of
different tumor types. However, the majority of patients do
not respond to these agents, and indeed some tumor types
appear particularly resistant.
Key questions still remain as to why some tumors escape
immune control  while  others  do  not.  For  example,  what
determines why some tumor cells are eliminated, while other
tumor clones progress further into equilibrium and escape?
In addition, what has occurred in the large proportion of
patients who have no obvious or apparent immune reaction
with their cancer, and did they ever develop one? If not, can
one be engineered? Can the immune system be stimulated
into developing a robust antitumor immune response? Will a
personalized  cancer  immunotherapeutic  strategy  ever  be
designed  specifically  for  an  individual  patient  and  their
individual tumors in the future?
Current immunotherapeutic
strategies
The CTLA4 monoclonal antibody ipilimumab was the first
checkpoint inhibitor to be approved by the U.S. Food and
Drug Administration (FDA). CTLA4 is expressed on T cells
and  when  bound  to  its  ligand  B7  on  DCs,  prevents  the
required co-stimulatory  signal  from activating the  T cell.
Ipilimumab  through  CTLA4  blockade  releases  this
checkpoint  causing  T  cell  activation.  Additionally,
ipilimumab causes antibody-dependent cellular cytotoxicity
dependent depletion of Treg cells at the site of the tumor24
Ipilimumab, with or without a gp100 peptide vaccine, was
the  first  systemic  agent  to  improve  OS  in  patients  with
metastatic  melanoma,  as  compared  with  gp100  alone.
Although  objective  antitumor  response  rates  were  low
(~10%),  approximately  20%  of  patients  had  a  durable
response out to 10 years. Immunological memory, one of the
cardinal  features  of  the  adaptive  immune system may be
responsible for this prolonged response. Specifically this is
the ability of the adaptive immune system to provide long
lived  and  maintained  responses  to  specific  epitopes  or
antigens25.  This sustained benefit 10 years after treatment
highlights the potential of immunotherapy and the role of
immunotherapy  in  raising  the  tail  of  the  survival  curve.
Treatment was not without toxicity however, with 10%-15%
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grade 3-4 immune related adverse events (irAE) and overall
45%  grade  3-4  adverse  events  (AE).  There  were  also  14
(2.1%) treatment related deaths26,27.
Tremelimumab is another anti-CTLA4 antibody that when
tested  in  a  phase  3  trial  against  chemotherapy,  failed  to
provide a significant median OS advantage. However, the 3-
year survival was 20% in the tremelimumab arm, similar to
that seen with ipilimumab. Furthermore, a recent analysis of
clinical data from four phase 1 and 2 tremelimumab trials has
revealed long term responses with 20% 5-year survival and
15% 12-year survival28,29.
Subsequent  to  anti-CTLA4  antibodies  was  the
 
Figure 1   Current immunotherapeutic strategies with checkpoint inhibition.
 
Figure 2   Future combination strategies with checkpoint inhibition. Multiple strategies can be used in combination with checkpoint
inhibition to enhance the antitumor function of the immune system as shown. Immunogenic cell death can be promoted by chemotherapy,
radiotherapy, targeted therapies as well as novel agents. Antigen presentation can be enhanced using vaccine therapies, immune adjuvants
and other novel agents. Immune-suppression can be reduced or eliminated by attenuating suppressor cells and the microenvironment
milieu and effector T cell function can be enhanced. TRAIL-R, TRAIL-receptor; TNF-SF, tumor necrosis factor super family; IDO1, indoleamine
2,3-dioxygenase 1; CXCR2, chemokine (C-X-C Motif) receptor 2; LAG-3, lymphocyte-activation gene 3; TIM-3, T-cell immunoglobulin and
mucin-domain containing-3; GM-CSF, granulocyte-macrophage colony-stimulating factor
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development of antibodies that target the PD-1/PD-L1 axis.
PD-1  and  its  ligand  are  expressed  on  T  cells  and  tumor,
respectively.  PD-1,  when activated by PD-L1 has  a  direct
inhibitory effect  on the T cell,  preventing activation.  The
expression of PD-L1 by tumor is one of the key components
leading to immune exhaustion and subsequently immune
escape as described above.  Multiple agents targeting both
PD-1 and PD-L1 are in development across a multitude of
tumor types16.
Nivolumab, a monoclonal antibody against PD-1, has been
shown  to  improve  OS  in  patients  with  metastatic
melanoma30. It has also, when compared to docetaxel shown
superior OS as second line treatment in both squamous and
non-squamous non-small cell lung carcinoma (NSCLC)31,32.
Pembrolizumab, a monoclonal antibody also targeting PD-1,
has likewise demonstrated survival benefits in melanoma and
NSCLC33,34. Both nivolumab and pembrolizumab have been
compared  to  ipilimumab  in  patients  with  metastatic
melanoma and were found to have superior response rates
(30%-40%) and improved OS. Importantly because of the
selective nature of the immune activation, toxicity was much
lower with both drugs compared to ipilimumab34,35. Multiple
tumor types have been shown in early phase trials to benefit
from anti-PD-1 treatment  with  activity  seen in  renal  cell
carcinoma  (RCC),  glioblastoma,  small  cell  lung  cancer
(SCLC) ,  head and neck squamous cell  cancer  (HNSCC),
bladder cancer, gastro-esophageal cancer, and hepatocellular
cancer  (HCC).  Atezolizumab,  a  monoclonal  antibody
targeting PD-L1, is  earlier in development but has shown
clinically significant activity in melanoma, RCC, mismatch
repair (MMR) deficient colorectal carcinoma (CRC), bladder
cancer, and triple negative breast cancer (TNBC) amongst
other tumors. A number of other PD-1/PD-L1 antibodies are
also currently in development36.
Although the  full  potential  of  checkpoint  inhibitors  as
single agent therapy has not yet been fully elucidated, with
many early and late phase clinical trials still ongoing, what is
apparent is that not all patients will benefit from this novel
class of drugs. Certain tumors such as CRC appear to be less
immunogenic and have been associated with low response
rates  to checkpoint  inhibition37.  Furthermore,  even in so
called  immunogenic  tumors  such  as  melanoma,  a  large
proportion  of  patients  do  not  respond  to  single  agent
checkpoint inhibition34,35. Validated predictive biomarkers of
response and resistance have thus far been challenging to
develop for these novel inhibitors38. An alternative strategy is
to  use  immunotherapies  in  novel  combination regimens,
which holds great promise in broadening the applicability
and increasing the effectiveness of immunotherapy.
A better understanding of the underlying mechanisms that
underpin the immune response to tumors has identified a
number of potential targets that have the ability to augment
the  response  to  checkpoint  inhibition  when  used  in
combination therapy36. Robust preclinical and early clinical
evidence  point  to  antitumor  synergies  in  combining
immunotherapies  by improving antitumor responses and
durability through the stimulation of the memory immune
response. The basic biological rationale for combining such
therapies is  to increase the immunogenicity of the tumor,
thereby leading to improved antitumor effects39. There are
multiple different approaches that can be taken in order to
do  this:  enhancing  antigen  presentation  and  major
histocompatibility complex (MHC) class I expression, tumor
microenvironment  changes  that  make  immune  response
more  favorable  such  as  downregulation  of  Treg  cells  or
enhancing T cell infiltration, and targeting the effector T cell
with stimulatory measures or blockade of inhibition40.
Multiple  different  therapies,  both  approved  and  in
development,  have been identified as showing promise in
combination with immunotherapy (Table 1). Chemotherapy,
radiotherapy,  targeted  therapies  (small  molecule  and
antibody), vaccine therapy and immunotherapies have all
shown  promise,  although  it  is  only  through  thorough
understanding  of  the  underlying  biology  that  rational
combinations and schedules can be designed36,39,40.
Combinations with chemotherapy
Emerging evidence indicates that one of the mechanisms of
actions  of  chemotherapy is  via  activation of  the  immune
system through multiple pathways41. Cytotoxic cell death and
subsequent  antigen  release  is  also  thought  to  provide
immune  stimulation,  common to  many  chemotherapies.
Moreover, some chemotherapies, such as cyclophosphamide
have been shown to reduce the number of circulating Treg
cells, which are a key component in immunosuppression42. A
number of different chemotherapies, including gemcitabine
have  also  been  shown  to  reduce  MDSCs  and  hence
interferon-gamma,  which  have  inhibitory  roles  in  the
immune  response43.  The  dual  role  of  cytotoxicity  and
immune activation from chemotherapy has  provided the
biological  rationale for the development of  combinations
with immunotherapy.
One of the earliest combinations tested was ipilimumab
and  dacarbazine  in  a  large  phase  3  trial  comparing
dacarbazine alone to dacarbazine with ipilimumab. OS was
significantly  improved  in  the  combination  arm  versus
dacarbazine alone [hazard ratio (HR) 0.72, P=0.001, median
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Table 1   Selected trials involving combination with immunotherapy
Agents tested Study details Main outcomes Adverse events Target Author, year
Chemotherapy
combinations with
immunotherapy
Dacarbazine (D) vs.
ipilumamab +
dacarbazine (I+D)
Phase 3 randomised 480
pts metastatic melanoma
Median OS I+D 11.2
months vs. D 9.1 months
(HR=0.72 P=0.001); I+D 3
y survival 20.8% vs. D
12.2%
G3/4 AE I+D 56%, D 40%;
G3 irAE I+D 41%, D 6%
CTLA4 Robert, 2011
Carboplatin + paclitaxel
(CP) vs. CP + ipilimumab
concurrent (CPIcon) vs.
CP+ipilumumab phased
(CPIph)
Phase 2 randomised 204
pts metastatic NSCLC
Phased ipilimumab irPFS
5.7 m vs. CP 4.6 m
(HR=0.72, P=0.05); ORR
CPIph 32%, CPIcon 21%,
CP 14%
G3/4 irAE CP 6%, CPIcon
20%, CPIph 15%
CTLA4 Lynch, 2012
Carboplatin + paclitaxel
(CP) vs. CP + ipilimumab
concurrent (CPIcon) vs.
CP+ipilumumab phased
(CPIph)
Phase 2 randomised 130
pts extensive small cell
lung cancer
Phased ipilimumab irPFS
6.4 m vs. CP 5.3 m (HR =
0.64, P=0.03) irORR CPIph
71%, CPIcon 49%, CP
53%
G3/4 irAE CP 9%, CPIcon
21%, CPIph 17%
CTLA4 Reck, 2012
Nivolumab +
cisplatin/gemcitabine or
cisplatin/pemetrexed or
carboplatin/paclitaxel
Phase 1, 56 pts metastatic
1st line NSCLC
ORR 43%, 1 y OS 59%-
87%
G3/4 AE 47% PD-1 Antonia,
2014
Pembrolizumab +
carboplatin/paclitaxel
(CP) or carboplatin/
pemetrexed (CPem)
Phase 1, 44 pts metastatic
NSCLC
Pembro + CP ORR 30%
Pembro + CPem ORR
58%
G3/4 AE Pembro +CP
15%; Pembro + CPem
38%
PD-1 Papadimitra
kopoulou,
2015
Atezolizumab + nab-
paclitaxel
Phase 1, 32 pts metastatic
TNBC
ORR 70.8%, SD 20.8% G3/4 AE 56% (41%
neutropenia)
PD-L1 Adams,
2015
Targeted therapy
combinations with
immunotherapy
Ipilimumab +
vemurafenib
Phase 1, 10 pts BRAF
mutant metastatic
melanoma
7/10 G2-3 hepatotoxcity CTLA4 BRAF Ribas, 2013
Durvalumab (Dur) +
trametinib (T) +
dabrafenib (Da)
durvalumab + trametinib
Phase 1, 41 pts metastatic
melanoma BRAF Mut
Dur+T+Da BRAF WT
Dur+T
ORR Dur+T+Da 16/21
(76%), Dur+T 6/20 (30%)
G3/4 AE Dur+T+Da 17
40%, Dur+T 17 40%
PD-L1
BRAF/MEK
Ribas, 2015
Tremelimumab +
sunitinib
Phase 1, 21 pts metastatic
RCC
PR 9/21 pts 43% 9/29 DLT 31% (3 acute
renal failure)
CTLA4 VEGF Rini, 2011
Nivolumab (N) + sunitinib
(S) or pazopanib (P)
Phase 1, 37 pts metastatic
RCC
ORR N+S 17/33 (52%)
N+P 9/20 (45%)
G3/4 AE N+S 24/33
(73%), N+P 12/20 (60%)
PD-1 VEGF Amin, 2014
Ipilimumab +
bevacizumab
Phase 1, 46 pts metastatic
melanoma
ORR 17%, clinical benefit
rate 64%
G3/4 AE 13/46 CTLA4 VEGF Hodi, 2014
Vaccine therapy
combinations
GVAX + CRS-207 vs.
GVAX
Phase 2 randomized 90
pts metastatic pancreatic
carcinoma
Median OS GVAX+CRS
6.1 months vs. 3.9
months m GVAX
(HR=0.59; P=0.02)
Gvax+CRS 4/61 G3
transaminitis; 5/61 G3/4
lymphopenia
Vaccine Le, 2015
Table 1 (continued)
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OS 11.2 months vs.  9.1 months,  3-year survival  20.8% vs.
12.2%]27. This study, in conjunction with a separate phase 3
study led to the approval of ipilimumab as a single agent for
the treatment of metastatic melanoma. It is unclear, however,
if the combination is required or only ipilimumab as there
was  no  ipilimumab  alone  arm  in  this  trial.  However,  an
earlier phase 2 study comparing dacarbazine and ipilimumab
vs. ipilimumab alone demonstrated improved response rates
of 15% vs. 5% and improved survival of 14.3 months (95%
CI, 10.2-18.8) vs. 11.4 months (95% CI, 6.1-15.6)44. Despite
this, the approval and widespread use of ipilimumab is as a
single agent.
Ipilimumab has also been combined with carboplatin and
paclitaxel in two separate studies in NSCLC and SCLC. These
studies  also  evaluated  the  timing  of  ipilimumab  in
relationship  to  chemotherapy.  It  was  demonstrated  that
phased treatment with ipilimumab, starting after 2-4 cycles of
chemotherapy,  provoked  superior  immune  responses
compared  to  concurrent  treatment.  This  suggests  that
'induction chemotherapy' has a role in causing cell death and
antigen release, as well as stimulating an immune response
that is then potentiated by the CTLA4 blockade45,46.
Treatment-related toxicity is increased when CTLA4 and
chemotherapies  are  combined44.  In  the  phase  2  trial
comparing ipilimumab vs. ipilimumab/dacarbazine, the rate
of grade 3 toxicity was 17.1% vs. 7.7% for the combination
and single agent, respectively44. Likewise, in the phase 3 trial
of ipilimumab/dacarbazine vs. dacarbazine, the rate of grade
3-4 immune-related adverse events was approximately 40%.
Interestingly,  20%-30% of patients experienced grade 3-4
liver  toxicity27.  This  compares  to  approximately  4%
hepatotox ic i ty  in  o ther  t r ia l s  wi th  ip i l imumab
monotherapy47.  One  possible  explanation for  this  is  that
dacarbazine,  which  can  result  in  hepatotoxicity,  causes
hepatic  cell  death and the release of  hepatic  specific  neo-
antigens. When this is combined with T cell activation from
Table 1   (continued)
Agents tested Study details Main outcomes Adverse events Target Author, year
T-VEC+ipilimumab Phase 1, 19 pts metastatic
melanoma
ORR 41% G3/4 AE 32% CTLA4 Puzanov,
2014
T-VEC+pembrolizumab Phase 1, 21 pts Not reported G3/4 AE 29% PD-1 Long, 2015
Immunotherapy
combinations
Nivolumab (N) +
ipilimumab (I) vs.
nivolumab (N) vs.
ipilimumab (I)
Phase 3 randomized 945
pts metasatic melanoma
Median PFS N+I 11.5
months, N 6.9 months, I
2.9 months (HR N+I vs. I
0.57; 99.5% CI, 0.43 to
0.76; P<0.001; ORR N+I
57.6%, N 43.7%, I 19%
G3/4 AE N+I 55%, N
16.3%, 27% I
CTLA4 PD-1 Larkin, 2015
Pembrolizumab (P) +
ipilimumab (I)
Phase 1, 17 pts metastatic
NSCLC
ORR 54% G3/4 AE 2/17 (6%) pts CTLA4 PD-1 Patnaik,
2015
Pembrolizumab (P) +
ipilimumab (I)
Phase 1, RCC, melanoma ORR 6/17 pts (35%) G3 AE 6/19 (31%) pts CTLA4 PD1 Atkins, 2015
Durvalumab (Du) +
tremelimumab (T)
Phase 1, 61 pts metastatic
NSCLC
ORR 26%, SD 35% G3/4 AE 31% CTLA4 PD-
L1
Antonia,
2015
Ipilimumab +
epacadostat
Phase 1, 40 pts
melanoma
ORR 30%, SD 30% DCR
30% pts with previous
immunotherapy
G3 AE 23% CTLA4 IDO1 Gibney,
2015
Ipilimumab + indoximid Phase 1, 9 pts melanoma Not reported No DLT, 1/7pts colitis CTLA4 IDO1 Zakharia,
2015
Pembrolizumab +
epacadostat
Phase 1, 54 pts advanced
solid tumors
ORR 10/19 (53%) G3/4 irAE 8% PD-1 IDO1 Gangadhar
2015
patients (pts); non small cell lung carcinoma (NSCLC); small cell lung cancer (SCLC); objective response rate (ORR); partial response (PR);
stable disease (SD); disease control rate (DCR); adverse events (AE); immune related adverse events (irAE); dose limiting toxicity (DLT);
progression free survival (PFS); overall survival (OS); immune related objective response rate (irORR); programmed cell death 1 (PD-1);
programmed cell death 1 ligand (PD-L1); cytotoxic T lymphocyte antigen 4 (CTLA4); indoleamine 2,3-dioxygenase 1 (IDO1); vascular
endothelial growth factor receptor (VEGFR).
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ipilimumab, hepatotoxicity may subsequently ensue. With
regards  to  hepatic  toxicity,  there  were  conflicting  results
between  NSCLC  and  SCLC  studies,  with  high  rates  in
patients with SCLC and low observed rates in the NSCLC
trial,  suggesting  that  other  patient-derived  factors  also
interplay with toxicity45,46.
There  are  currently  limited  data  for  PD-1/PD-L1
combinations  with  chemotherapy,  although  multiple
ongoing  studies  are  currently  looking  at  various
combinations.  A  phase  1  study  of  nivolumab  with  three
different  chemotherapy  regimens:  cisplatin/gemcitabine,
cisplatin/pemetrexed, or carboplatin/paclitaxel in first line
NSCLC patients showed overall response rates of 43%, with
grade 3-4 adverse events in 47%. Notably, eleven patients
withdrew  from  treatment,  because  of  treatment-related
toxicities, 10 during nivolumab monotherapy, a rate that is
higher than usually seen with nivolumab when given as a
single agent48. Pembrolizumab has also been combined with
doublet chemotherapy in patients with metastatic NSCLC.
Forty-four patients were treated with pembrolizumab 2 or 10
mg/kg and either carboplatin AUC6+paclitaxel 200mg/m2
(cohort A) or carboplatin AUC 5 + pemetrexed 500 mg/m2
(cohort C). Grade 3-4 toxicities were seen in 15% and 38% of
cohort  A  and  C,  respectively.  Common  toxicities  were
transaminitis, colitis and rash. Preliminary objective response
rate (ORR) was observed in 30% and 58%, respectively49.
Atezolizumab has been combined with the nanoparticle
albumin-bound paclitaxel (nab-paclitaxel) in a phase 1 trial
in patients with metastatic TNBC. Objective response rates of
70.8% and stable disease in 20.8% were observed. Grade 3
and 4 adverse events occurred in 56% of patients with 41%
experiencing grade 3 or 4 neutropenia50.
Combinations with radiotherapy
Radiotherapy  has  been  reported  to  stimulate  immune
responses. Indeed, the well recognized albeit rare abscopal
response  appears  to  be  immune-mediated51,52.  Direct
cytotoxicity  by ionizing radiation leads to increased neo-
antigen  expression  and  the  induction  of  inflammatory
cytokines that  attract  T cells  and DCs,  as  well  as  enhance
antigen  uptake  and  cross  presentation  by  DCs53.  Animal
models have shown promising synergy between anti-CTLA4
and anti-PD-L1 antibodies in inducing immune mediated
response5 4 , 5 5 .  It  has  also  been  demonstrated  that
hypofractionated radiotherapy is superior to solitary doses in
inducing  immune  responses56.  Illustrating  the  potential
benefit  of  radiotherapy  is  a  case  report  of  a  patient  who
received palliative radiotherapy to a bone metastasis many
months  after  the  development  of  disease  progression
following ipilimumab therapy.  Despite the length of time
after receiving ipilimumab, there was significant regression of
multiple metastatic lesions distant to the radiotherapy site57.
A number of trials assessing the combination of radiotherapy
and novel immunotherapies are currently underway58.
Cryotherapy and other ablative therapies may also induce
immune responses via antigen release and damage-associated
molecular  patterns  that  activate  immune  responses59.
Preclinical models have shown synergy between radiotherapy
and CTLA4 blockade. A pilot study of 20 patients has looked
at  combining  ablative  therapies  [transarterial  chemo-
embolization (TACE) or  radiofrequency ablation (RFA)]
with tremelimumab in patients with HCC. The combination
was well  tolerated with no dose limiting toxicities (DLFs)
observed. Four of 12 (33%) patients with evaluable disease
outside the field of TACE/RFA had objective responses60.
Combinations with molecularly
targeted agents
Molecularly  targeted  therapies  also  show  promise  in
combination  with  immunotherapy.  There  is  increasing
evidence  that  one  of  the  mechanisms  of  certain  targeted
agents is through immune modulation61,62. Indeed, although
drug  resistance  is  a  frequent  occurrence  with  targeted
inhibitors,  such  as  imatinib  in  gastrointestinal  stromal
tumors  (GIST)  and  BRAF/MEK  inhibitors  in  melanoma,
there appears to be a subset of patients who are long term
responders63,64. Furthermore, there is also some evidence, in
patients with GIST treated with imatinib, that induction of
an  immune  response,  as  measured  by  interferon-gamma
levels,  is  predictive  of  improved  survival  and  long  term
responses63.  This  is  suggestive  that  it  may  be  through
underlying  immune  mechanisms  that  some  targeted
therapies may deliver long term responses.
BRAF inhibitors have substantial activity in BRAF V600E
mutant melanomas and other BRAF mutant tumors65. They
however appear to cause a paradoxical activation of the RAF
pathway in RAF wildtype cells. It has been shown that this
activation also occurs in T cells and results in T cell activation
and proliferation,  which could be potentiated further  via
checkpoint  blockade62 .  Tumor  biopsy  studies  have
demonstrated increased tumor infiltrating lymphocytes and
neoantigen expression in patients treated with dabrafenib
and trametinib, compared to baseline. This preclinical work
provided the rationale for undertaking combination studies
of  immune checkpoint  and BRAF/MEK  inhibitors.  It  was
predicted  that  the  combination  of  these  two  different
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modalities of therapies may potentially synergize the high
response rates of BRAF  directed therapy with the durable
responses of checkpoint inhibition66. Unfortunately, a phase
1 trial of the BRAF inhibitor vemurafenib and ipilimumab in
advanced  melanoma  was  closed  early  after  considerable
toxicity was observed. Starting at the recommended dose of
each drug (960 mg vemurafenib and 4 mg/kg ipilimumab),
four of six patients in the first cohort developed dose limiting
grade 3 elevations in liver function tests. In a second cohort
assessing  720  mg  of  vemurafenib  with  4  mg/kg  of
ipilimumab,  three  of  four  advanced  melanoma  patients
experienced  grade  2-3  liver  transaminitis.  Although  all
adverse  events  were  asymptomatic  and  reversible  with
glucocorticoids, the combination was deemed too toxic and
the study was closed to further accrual67.
Despite  this  setback,  great  interest  remains  with  the
combination strategy of targeting the immune checkpoint
and BRAF/MEK signalling pathway. In view of the favorable
toxicity profile and selective T cell activation of PD-1/PD-L1
antibodies compared to CTLA4 inhibitors, a phase 1 trial is
currently investigating the combination of the anti-PD-L1
agent durvalumab with the MEK  inhibitor trametinib or a
triple  regimen  with  the  BRAF  inhibitor  dabrafenib  and
trametinib66.  In  BRAF  mutant  patients,  the  full  doses  of
dabrafenib and trametinib were combined with 3 mg/kg and
10  mg/kg  of  durvalumab.  BRAF  wildtype  patients  were
treated  with  trametinib  and  durvalumab  both  in
combination and sequentially  with  induction trametinib.
Treatment  appeared  tolerable,  with  no  differences  in
toxicities observed across the patient groups,  with mostly
BRAF/MEK inhibitor toxicities observed and low incidences
of grade 3 autoimmune toxicities. Antitumor efficacy appears
promising, but longer follow-up is required to provide more
data on efficacy66.
Combining vascular endothelial  growth factor receptor
(VEGFR)  inhibitors  with  immunotherapeutic  agents  has
demonstrated mixed results. A phase 1 trial of tremelimumab
with  sunitinib  was  discontinued  early  due  to  treatment-
related toxicities with high rates of rapid onset renal failure68.
In  contrast,  the  combination  of  nivolumab  with  either
sunitinib or pazopanib appeared well tolerated with durable
antitumor  responses  reported69 .  The  choice  of  the
immunotherapy backbone in this situation is likely key to the
difference  in  toxicity  seen.  CTLA4 blockade  causes  non-
specific and widespread T cell activation, whereas blocking
the PD-1/PD-L1 axis increases T cell responses only in tissues
expressing  PD-L1,  providing  a  much  more  selective  and
specific  response  on  tumor-directed  T  cells36.  A  similar
parallel is seen with the development of hepatotoxicity with
the combination of vemufarenib and CTLA4 inhibitors, in
contrast  to  the  seemingly  more  tolerable  combination of
dabrafenib/trametinib and durvalumab.
The  cancer  vasculature  has  multiple  roles  in  the
modulation of  tumor immune responses70.  In  particular,
vascular  endothelial  growth  factor  (VEGF)  is  known  to
suppresses DC maturation and can modulate lymphocyte
endothelial trafficking71. Sunitinib has been shown to reduce
MDSCs  in  the  tumor  microenvironment72.  As  such,
considerable potential exists for the combination of immune
checkpoint therapy and VEGF targeted therapy.
Bevacizumab has been combined with ipilimumab in a
phase  1  trial  of  46  patients  with  metastatic  melanoma.
Treatment-related  toxicities  were  manageable,  although
interestingly  there  was  one  episode  of  immune mediated
arteritis. Antitumor activity was higher than would have been
expected  for  either  agent  alone  with  17% ORR and  64%
clinical benefit rate73. Bevacizumab has also been combined
with nivolumab as part of a maintenance strategy in NSCLC
after platinum-based chemotherapy with significant increase
in toxicity above nivolumab alone74. Atezolizumab has also
been  tested  in  combination  with  bevacizumab  with  or
without FOLFOX chemotherapy in a phase 1 trial with no
increase in toxicity observed, although antitumor activity
data are awaited75.
The antibody drug conjugate brentuximab vedotin, which
is highly active in Hodgkin’s lymphoma, is also being looked
at in combination with immunotherapy. Increased antigen
release caused by brentuximab has the potential to synergize
with  checkpoint  blockade76.  A  number  of  clinical  trials
combining  brentuximab  vedotin  with  nivolumab  and/or
ipilimumab are underway77.
Combinations with vaccine therapies
Vaccine  therapy  has  a  long  history  as  single  agent
immunotherapy  with  generally  disappointing  results.
Although vaccines are able to provoke immune responses,
translating this  observation into clinical  benefit  has  been
challenging78.  Armed with  a  better  understanding  of  the
immune  system,  new  vaccine  models  have  now  been
developed and are being used in combination with increasing
success. A number of different strategies have been used in
combination with checkpoint inhibition to increase antigen
presentation via a range of vaccination approaches, ranging
from simple peptide to more complex engineered cellular
vaccines, DC vaccines, virus vectored vaccines and oncolytic
viral vaccines78.
Single  peptide  vaccines  in  combination  with  CTLA4
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blockade  have  been  shown  to  be  able  to  induce  peptide
specific immune responses. However, a large phase 3 study
combining gp100 peptide with ipilimumab did not provide
any  additional  cl inical  benefit  above  and  beyond
ipilimumab26.
Sipuleucel-T is an autologous dendritic cell vaccine that
targets prostatic acid phosphatase and has been shown to
improve OS in patients with metastatic castration-resistant
prostate  cancer  (CRPC).  It  does  so  however  without
impacting on PFS or affecting prostate specific antigen (PSA)
levels79. Sipuleucel-T has now been combined with the next
generation  androgen  receptor  inhibitor  enzalutamide  in
patients with CRPC. Early results of a phase 2 trial involving
this  combination  have  shown  that  that  this  regimen  is
tolerable, and results in objective radiological and PSA tumor
marker responses80.  Interestingly,  the sequencing of  both
therapies did not affect patient outcomes with similar results
seen with concurrent or sequential treatment80.
An alternate DC vaccine has been tested in combination
with  docetaxel/prednisolone  in  patients  with  CRPC.
Importantly, the addition of immunotherapy in the form of
DC  therapy  did  not  seem  to  increase  toxicity.  All  of  the
toxicities  observed  were  grade  1-2  and  were  within  the
recognized range of adverse events for docetaxel. Although
this was a single arm study with no comparator arm, efficacy
was potentially enhanced with a median PFS of 19 months
observed compared with an expected PFS of 13 months based
on the Memorial Sloan Kettering Cancer Centre (MSKCC)
nomogram.  Furthermore ,  the  adminis trat ion  of
chemotherapy  and  corticosteroids  did  not  prevent  the
induction of antitumor T cells, but did lead to a decline in
immune-inhibitory Treg cells81.
Autologous  tumor  vaccines  also  show  promise  as
combination  immunotherapy.  GVAX  is  a  vaccine  with
allogeneic  tumor  cells  that  have  been  transfected  with
granulocyte and macrophage colony stimulating factor (GM-
CSF).  A  recent  phase  2  study  in  patients  with  metastatic
pancreatic carcinoma of GVAX with or without CRS-207,
live-attenuated  Listeria  monocytogenes-expressing
mesothelin, led to significant improvements in median OS.
Median OS was 9.7 vs.  4.6 months (arm A vs.  B; HR: 0.53;
P=0.02)82.  GVAX  has  previously  been  combined  with
ipilimumab in prostate cancer and pancreatic cancer trials
and found to be a safe combination with some evidence of
clinical  benefit,  although further research is  required83,84.
Current  studies  are  underway combining GVAX/CRS207
with nivolumab85.
Oncolytic viruses are treatments that may be wildtype or
modified  live  viruses  that  provide  a  similar  role  to
vaccination  by  replicating  in  tumor  cells  and  releasing
antigenic  proteins.  The  most  advanced oncolytic  virus  is
talimogene  laherparepvec  (T-VEC),  which  is  a  herpes
simplex virus that has been genetically modified via deletion
of viral genes to reduce pathogenicity and insertion of the
GM-CSF  gene.  The  expression  of  GM-CSF  in  the  virus
promotes  local  GM-CSF  production  that  aids  in  the
recruitment and activation of antigen presenting cells (APCs)
and  then  T  cell  responses.  In  a  phase  3  study  with
intraregional  injection  of  T-VEC  compared  to  GM-CSF
alone, there was an increase in median OS from 18.9 to 23.3
months with a P-value very close to significance (P=0.051).
The ORR was 26.4% in the T-VEC group, with 16% durable
responses.  A different  oncolytic  virus  coxsackie  virus  has
similar responses in patients with metastatic melanoma86. On
the  basis  of  this  trial,  T-VEC  has  recently  gained  FDA
approval for the treatment of metastatic melanoma.
There  is  also  robust  preclinical  rationale  for  the
combination of T-VEC with anti-CTLA4 or anti-PD-1/PD-
L1  inhibitors.  A  phase  1  trial  in  patients  with  advanced
melanoma  combining  T-VEC  with  ipilimumab  led  to
response rates of 41%. Adverse events were manageable, with
32%  grade  3-4  adverse  events  reported87,88.  T-VEC  in
combination with pembrolizumab has been evaluated in a
phase 1b/3 trial in patients with metastatic melanoma, with
safety  data  for  the  phase  1  component  recently  reported.
Combination  therapy  at  full  doses  of  each  individual
component was tolerable, with no DLTs observed and 29%
grade 3-4 treatment-related adverse events reported, most
commonly  rash,  fatigue  and  pyrexia.  This  trial  has  now
commenced the phase 3 component87.
Combinations with
immunotherapies
Combination of anti-CTLA4 and anti-PD-1 has been shown
to  improve  outcomes  at  the  risk  of  increased  toxicity.
Nivolumab  and  ipilimumab  given  in  combination  was
compared  to  single  agent  nivolumab  and  single  agent
ipilimumab for untreated metastatic melanoma. Response
rates  were  19%,  43.7%,  and  57.6%  in  the  ipilimumab,
nivolumab and combination arms, respectively. OS has not
yet been published but PFS was also significantly improved.
Median PFS was 2.9 months, 6.9 months, and 11.5 months,
respectively  for  the  three  arms.  Although  the  trial  was
powered only  to  compare nivolumab vs.  ipilimumab and
combination vs. ipilimumab, even taking this into account
the HR for PFS between combination and nivolumab was
0.74  (95% CI  0.6-0.092)  in  an  exploratory  analysis.  This
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conclusively  showed that  the combination of  CTLA4 and
treatment was superior to either as single agent35.
Toxicity,  however,  was higher in the combination arm,
with 27%, 16% and 55% grade 3 or 4 adverse events for the
ipilimumab, nivolumab and combination arms, respectively.
Despite the high level of adverse events, it is worth noting
that patients who were required to come off treatment due to
irAE had an overall higher response rate of 67%, with many
of these after cessation of treatment35. More recent studies
have  demonstrated  that  the  need  to  treat  irAE  with
corticosteroids  does  not  impact  on outcomes89.  Ongoing
studies  are  looking  at  the  combination  in  other  tumor
histologies.
In a pre-planned subgroup analysis,  the benefit  for the
combination  group  was  seen  predominantly  in  patients
w h o s e  t u m o r s  w e r e  n e g a t i v e  f o r  P D - L 1  o n
immunohistochemistry at  study entry.  This suggests,  that
patients who are PD-L1+ have an immune response that has
been inactivated through the PD-1/PD-L1 checkpoint.  As
such they did not benefit from CTLA4 blockade that causes
non-specific T cell activation. In contrast the patients whose
tumors were PD-L1 negative, needed the CTLA4 blockade to
activate T cells and move them into tumors, and subsequent
further PD-1 blockade maintains the immune response in the
tumors35.
Pembrolizumab has been combined with ipilumumab in a
phase 1 trial for patients with previously treated advanced
NSCLC,  the  results  of  which  have  been  presented  at
American  Society  of  Clinical  Oncology  (ASCO)  annual
meeting 2015. The toxicity profile was manageable with only
2/17 grade 3 events, and no DLT. Efficacy results revealed
54% complete response (CR) and partial response (PR) rates
across all dosing cohorts. Three separate dose combinations
were investigated, pembrolizumab 10 mg/kg + ipilumumab 3
mg/kg, 10 + 1 and 2 + 1. Despite small numbers of patients,
the lower dose combinations did not appear to compromise
efficacy90.  This  same  combination  with  pembrolizumab
2mg/kg and ipilimumab 1 mg/kg every three weeks has also
been tested in a phase 1 study in patients with metastatic
melanoma or metastatic RCC. In a preliminary report, 6/9
patients  experienced  DLTs-  grade  3  irAE,  which  met  the
prespecified definition of tolerability. PRs were seen in 6/17
(35%) evaluable patients91.
Durvalumab  and  tremelimumab  were  studied  in  a
combination phase 1 dose escalation trial in patients with
NSCLC. Increasing doses of durvalumab were tolerable up to
20 mg/kg every 2 or 4 weeks with a constant tremelimumab
dose  of  1  mg/kg,  however  at tempts  to  increase
tremelimumab resulted in increasing irAE, most frequently
colitis. About 18% of patients required discontinuation. The
maximal  tolerated dose  (MTD) has  not  yet  been defined.
ORR was 26% and SD 35% across all cohorts. Importantly, 3
of  10  patients  with  PD-L1-negative  tumors  had  partial
responses,  underlining  the  ability  of  the  combination
treatment to overcome negative PD-L192.
An alternative approach has been combination with agents
that act to enhance the innate immune response. Agents such
as toll-like receptors agonists have shown significant efficacy
in  tumor  models  and  have  been  shown  to  enhance  the
activity of anti-CTLA and PD-1 antibodies. PF-3512676 and
antibody to toll-like receptor 9 (TLR9) was explored in a
combination  with  tremelimumab  in  a  phase  1  study  in
patients with solid tumors and melanoma. Two of 17 patients
had partial responses. At full doses of tremelimumab and the
TLR9 agonist however significant toxicity was seen with 2
DLT  of  grade  3  diarrhea  that  was  manageable  with
corticosteroids. Furthermore, there was an increase in late
immune mediated toxicity occurring outside the three week
DLT period93.
Pegylated-interferon is another such agent that helps to
activate the innate immune response that has shown early
evidence  of  efficacy  in  combination  with  checkpoint
blockade. Two small trials in combination with ipilimumab
and tremelimumab reported 30% and 24% response rates in
patients  with  melanoma,  higher  than would  generally  be
expected  for  these  agents.  These  combinations  however
require further validation in larger trials94,95.
Combinations with other checkpoint
inhibitors
Similar to how PD-1 is unregulated by cancer cells in order to
produce T cell exhaustion, tumors may also upregulate other
proteins  that  act  to  dampen  T  cell  activity.  T  cell
immunoglobulin domain and mucin domain-3 (TIM3) and
lymphocyte  activating  gene  3  (LAG3)  are  two  such
checkpoint  molecules,  with  novel  antibody  therapeutics
targeting  these  key  targets  already  in  precl inical
development96.
LAG3 is expressed on CD4+ cells and binds to MHC class
2 molecules and appears to have a key role in Treg function.
It is also overexpressed on CD8+ T cells in models of tumor-
induced tolerance. Blockade of LAG3 in preclinical models
does not completely restore T cell function, but there does
appear to be potent synergy with anti-PD-1 treatments in
animal  models,  which  are  able  to  reject  even  poorly
immunogenic tumor97 This therefore raises the prospect of
clinical synergy when given with anti-PD-1 therapy. Multiple
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agents are currently in clinical development, including the
novel anti LAG3 antibody BMS-986016, which is currently in
phase 1 testing in combination with nivolumab36.
TIM3 is  a  glycoprotein receptor  that  is  expressed on T
cells, which has been shown to be present on PD-1+ CD8+
exhausted tumor infiltrating lymphocytes. Animals that lack
TIM3 do not develop overt autoimmunity, suggesting a more
subtle  role  in  immunosuppression  compared  to  PD-1.
However, in animal models pre-disposed to autoimmunity,
blockade  of  TIM3  can  accelerate  the  development  of
autoimmunity98.  Synergy  with  PD-1  blockade  has  been
observed in animal models, with some evidence that triple
therapy  with  TIM3/PD-1/4-1BB  may  provide  further
advantages98,99. Monoclonal antibodies targeting TIM3 are
currently in preclinical development36.
Combinations with immune pathway
agonists
Also in development are antibodies that target agonists of T
cell  co-stimulation  and  as  such  stimulate  the  immune
response. These stimulatory receptors belong to the tumor
necrosis  factor  receptor  super  family  (TNFRSF).  Tumor
necrosis factor (TNF) is  an important immune stimulant,
with TNF having long been used with marginal efficacy in
melanoma and sarcoma100. The TNFRSF includes a number
of  different  receptors  some of  which  are  in  development
currently and hold promise in providing synergistic activity
with checkpoint blockade36.
4-1BB is a TNF receptor that is found on both T cells and
natural killer (NK) cells with a co-stimulatory role. It has also
been found on neutrophils, myeloid lineage and some DCs.
Activation of 4-1BB has been shown to activate T cells and
increase survival and effector functions. It plays important
roles in immune homeostasis through Treg function as well
as  developing  antitumor  immune  memory.  As  such  the
results of activation can be immune activation or restriction,
and is most likely context development101. Preclinical data
suggests likely synergistic activity with checkpoint inhibitors,
but also with antibodies that cause antibody-dependent cell-
mediated cytotoxicity (ADCC) as this process upregulates 4-
1BB102,103. Two molecules, urelumab and PF-05082566 are in
development in both single agent phase 1 and combination
studies. A single agent phase 2 with urelumab had high rates
of hepatotoxicity and was closed early, leading to efforts to
better  define  a  safe  dose  in  currently  ongoing  studies104.
Urelumab  in  combination  with  elotuzumab  (NK  cell
activator and enhancing ADCC) is currently being tested in
patients with multiple myeloma105. Other trials combining
urelumab with rituximab, cetuximab and pembrolizumab
amongst others are underway106. PF-050825266 was shown
to be tolerable,  with activity  seen in 9  of  24 patients  in  a
phase 1 study107. Combination therapy with rituximab has
been  reported  in  a  phase  1  study  and  found  to  safe  and
efficacious in non-Hodgkin's lymphoma (NHL)108. It is also
undergoing testing in combination with pembrolizumab36.
OX40  or  tumor  necrosis  factor  receptor  superfamily,
member 4 (TNFRSF4), also known as CD134 is found on
multiple  T  cell  subsets,  neutrophils  and  NK cells,  and  is
believed to have a role in the survival of activated T cells and
the  establishment  of  T  cell  memory.  It  is  expressed
transiently  after  T  cell  activation109.  There  is  preclinical
evidence for its use in combination with 4-IBB agonists, as
well  as  anti-PD-1,  CTLA4  and  TIM3  antibodies99,110,111.
9B12, a mouse IgG1 anti-human OX40 monoclonal antibody
has  been  tested  in  prostate  cancer  in  combination  with
standard  treatments  and  shown  to  enhance  immune
activation via increased CD4+, CD8+ and NK cells, although
no antitumor responses were seen. Given the need for T cells
to  become activated first  to  express  OX40 it  may be  that
combination  with  an  agent  aimed  at  increasing  T  cell
activation is  the best  use of  OX40 agonists  rather than as
monotherapy109.  Further  fully  humanized  monoclonal
antibodies  are  currently  in  development,  in  particular
MEDI6469, an OX40 specific antibody, which is being tested
in  a  number  of  settings  including  single  agent  and  in
combination with tremelimumab and durvalumab112.
CD40 is expressed on APCs and B-cells among other cell
types rather than T cells. Its ligand CD40L is expressed on T
cells amongst multiple other cell types. Activation of CD40
induces APC maturation and expression of co-stimulatory
molecules that promotes T cell activation109. CP-870893, the
agonistic antibody to CD40 has been tested in combination
with tremelimumab in the phase 1 clinical trial setting113. An
objective  response  rate  of  27%  was  observed,  however
significant toxicity was also reported, with colitis and uveitis
found to be dose limiting. CD40 has been shown in models
to  increase  expression  of  PD-L1  on  tumor  infiltrating
macrophages  and  monocytes,  and  as  such,  there  is  good
rationale for combining CD40 targeted agents with anti-PD-1
inhibitors,  which  may  be  associated  with  relative  fewer
toxicities than tremelimumab114.
There are multiple other members of the TNFRSF that are
in preclinical  development and have promising potential.
Glucocorticoid-induced TNFR-related protein is expressed
on Treg cells  and may be upregulated in CD4 and CD8 T
cells. It has shown synergy in combination with anti-PD-1
antibodies in preclinical models115. CD27 is a co-stimulatory
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molecule expressed on effector T cells and memory B cells, as
well as some NK cells. CD27 appears to have an important
role in sustained T cell function as well as development of T
cell  memory  and  IgG  antibody  production  in  germinal
centers. An agonistic antibody CDX-1127 has been tested in a
phase 1 study in NHL and solid tumors, and was found to be
tolerable with evidence of antitumor activity. Combination
studies are currently being planned116. DR3 (TNFRSF25) and
its ligand TNF-like 1A are involved in immune homeostasis,
T cell  accumulation and cytokine production. Agonists to
DR3 have been shown to increase T effector populations and
may thus be another potential immunotherapy combination
partner117.
Finally,  herpes virus entry mediator (HVEM), which is
expressed  on  APC,  endothelium  and  lymphocytes,  is  a
receptor to multiple ligands including TNF family proteins
LIGHT and  B  and  T  cell  attenuator  (BTLA)  and  CD160.
Despite  a  member  of  the  TNF  super  family,  HVEM  is
inhibitory in its  actions on the immune system. However
depending  on  the  context  of  its  activation  can  also  be
stimulatory.  BTLA  binding  to  HVEM  is  an  important
suppressor  of  immune  activation,  and  is  known  to  be
unregulated in multiple tumor types. As such, it has great
potential as a target, however detailed understanding of its
mechanism of action will  be required in order to target it
effectively given the potential to either stimulate or inhibit
immune responses118.
Targeting the tumor
microenvironment
The  tumor  microenvironment  (TME)  through  multiple
complex  mechanisms  is  involved  in  the  development  of
immune  escape  and  immune-editing.  As  such,  multiple
targets  in  the TME exist  that  show promise  in increasing
tumor immunogenicity. One of the most developed targets in
this area is indoleamine 2, 3-dioxygenase 1 (IDO1), although
multiple other targets including MDSCs, chemokines, and
Treg cells are still in pre-clinical development40.
IDO1  is  a  cytosolic  enzyme  that  is  required  for  the
catabolism of tryptophan, an essential amino acid. IDO1 is
produced  by  tumor  cells  and  MDSCs  in  response  to
inflammatory signals, such as interferon-gamma. Increased
IDO1 levels lead to an increased breakdown of tryptophan
into  its  metabolites  which  are  known  to  supress  T  cell
activity119. Cancer cell production of IDO1 is thought to be a
key mechanism of TME immunosuppression. A number of
IDO1 inhibitors are in clinical development. For example,
GDC-0919,  a  small  molecule  potent  inhibitor  of  IDO1 is
currently  undergoing  phase  1  clinical  trial  testing.
Preliminary results suggest some evidence of activity with
44% patients having a best response of stable disease for 4
months.  Toxicity  was  manageable  with  one  DLT  of
gastrointestinal  haemorrhage,  and although 58% patients
developed  grade  3-4  adverse  events,  many  of  these  were
disease rather than treatment-related120.
Epacadostat (INCB024360) has been tested in single agent
phase 1 trials,  as well as in combination with ipilimumab.
The  combination  was  tested  in  patients  with  metastatic
melanoma, with three different dose levels of epacadostat.
The intermediate dose level of 50mg BD was well tolerated.
Grade  3  adverse  events  occurred  in  23%  of  patients.
Antitumor  activity  appeared  promising,  with  a  disease
control rate (DCR) of 60% (30% overall response rate) in
immunotherapy-naive patients  and 30% DCR in patients
who had received prior immunotherapy treatments. About
50% of patients who had either CR/PR or SD had durable
benefit  beyond  6  months.  The  activity  in  patients  with
previous immunotherapy was particularly promising as this
potentially  suggests  a  role  in  overcoming  resistance121.
Combination  with  pembrolizumab  in  a  phase  1  trial  of
patients with advanced solid tumors also showed promising
activity,  with tumor size reductions in 15 of  19 evaluable
patients and an objective response in 10 of 19 (53%) patients.
There were low rates of irAE (8%)122. A third IDO1 inhibitor
in  development  is  indoximod,  which  is  a  tryptophan
analogue. A combination study with ipilimumab in patients
with advanced melanoma has recently reported safety results,
with the combination found to be tolerable up to 1,200 mg
BID, which is the maximum biologically achievable dose of
indoximod. No DLTs were observed, and a phase 2 trial is
now planned123.
Tumor  growth  factor  Beta  (TGFβ)  is  a  cytokine  with
important  roles  in  the  TME  including  angiogenesis  and
immunosuppression. Overexpression is associated with poor
outcomes in multiple different tumor types124. LY2157299
(galunisertib) is a small molecule kinase inhibitor that blocks
TGFβ.  Preclinical  models  have  shown  synergy  with
chemotherapy and with anti-CTLA4125. A combination study
with nivolumab is currently being planned.
Antibodies targeting colony stimulating factor 1 receptor
(CSF-1R)  have  been  shown in  both  preclinical  and  early
phase  clinical  trials  to  increase  the  CD8/CD4  ratio  by
d e p l e t i n g  T r e g s  a n d  i n d u c i n g  d e p l e t i o n  o f
immunosuppressive macrophages in tumors. These effects
ra i se  the  potent ia l  for  the i r  combinat ion  wi th
immunotherapy, and future trials are planned126.
CXCR4  is  a  receptor  for  the  chemokine  CXCL12  and
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through  tumor  hypoxia,  has  been  shown  to  augment  an
immunosuppressive  tumor  microenvironment  through
multiple pathways including Treg localization127. Preclinical
studies  have  shown  antitumor  synergy  with  anti-PD-1
therapies,  raising  the  potential  for  further  combination
studies1 2 8 .  A  number  of  CXCR4  inhibitors  are  in
development, the most advanced being ulocuplumab, which
is currently being tested in combination with nivolumab129.
T a r g e t i n g  T r e g s  a s  a  m e a n s  o f  a u g m e n t i n g
immunotherapy also holds great promise. Tregs are known
to downregulate immune responses, and at least part of the
activity of ipilimumab is through the depletion of Tregs, as
well as the induction of effector T cell responses. A number
of antitumor agents are currently in development aimed at
reducing  Tregs.  For  example,  mogamulizumab  is  a
monoclonal  antibody  that  targets  CCR4,  which  is  highly
expressed on Tregs. Treatment with mogamulizimuab has
been  shown  to  reduce  Treg  counts  and  induce  immune
responses,  and  also  has  single  agent  activity  in  T-cell
leukemia130,131. Trials combining mogamulizumab and either
tremilimumab,  durvalumab  and  nivolumab  are  in
planning132,133. Focal adhesion kinase inhibitors (FAKi) have
also been shown to reduce Tregs and increase the CD8/CD4
ratios134.  The  FAK  inhibitor  VS-6063  is  currently  being
combined with pembrolizumab in a phase 1 trial135.
Trial designs for immunotherapy
combination strategies
What is important in the development of these combinations
is intelligent trial design based on a thorough understanding
of the underlying immunomodulatory mechanisms. Both the
scheduling and sequencing of drugs is important and needs
to be carefully considered. For example, unlike conventional
anticancer treatments, immunotherapy has the potential to
result in long lasting antitumor effects that may still be active
when  subsequent  treatments  are  delivered.  A  poignant
example is IL-2 and ipilimumab. When administered after
IL-2 therapy,  ipilimumab appears  to  be effective,  but  the
observed  toxicity  is  significantly  higher  than  would  be
expected from either drug alone136. In the case of ipilimumab
and PD-1 therapy, important data are drawn from the phase
1 combination study in which a treatment arm of patients
with advanced melanoma with prior ipilimumab exposure
received nivolumab.  Importantly,  toxicity  did not appear
higher in this group than would be expected for single agent
nivolumab137.
The  scheduling  of  different  antitumor  agents  in
combination may also be important. For example, the use of
induction  chemotherapy  prior  to  starting  ipilimumab
appears to be beneficial, likewise the use of hypofractionated
radiotherapy is superior to other schedules46,56. Furthermore,
with novel combinations of immunotherapies, timing in the
schedule is likely to be important, especially for targets that
are induced or appear transiently such as OX40.
Other important considerations to make when designing
immunotherapy combination early phase trials include the
incorporation of biomarker studies, monitoring of toxicities
and the determination of antitumor efficacy.
Incorporating biomarker studies into
immuno-oncology trials
As discussed in this review, anti-CTLA and anti-PD-L1/PD-1
antibody treatments have revolutionised the treatment of
some tumor types and have the potential to reform cancer
treatment  as  a  whole.  These  treatments  are  not  without
patient  risk  however  and  come  at  high  financial  costs,
therefore  identifying  biomarkers  predictive  of  response
and/or resistance is  essential.  Furthermore,  incorporating
biomarker enrichment strategies into early phase trials and
beyond  can  be  beneficial  as  it  allows  for  continuous
reassessment  and  refinement  of  the  biomarkers  and
technologies involved138.  Various immunologic correlates
with clinical benefit to anti-CTLA4/PD-1/PD-L1 have been
demonstrated in the literature, however a robust predictive
biomarker has yet to emerge139.
To date, the failure to relate immune response activation
with  clinical  benefit  may  in  part  be  due  to  current  assay
limitations, rather than a true lack of biological correlation.
For example, T cell immune response assays that measure the
activation of the immune response exist, however results of
such  assays  are  notoriously  inconsistent  between
laboratories140.  Harmonization  of  assay  protocols  and
reporting through the use of standard operating procedures
have  the  potential  to  reduce  inter-laboratory  variability
(http://miataproject.org/)  and  increase  the  odds  of
identifying previously unidentified predictors of response.
There have been conflicting studies on the usefulness of
PD-L1 expression in predicting responses to anti-PD-1/PD-
L1 antibody treatments,  in part perhaps due to the use of
different anti-PD-L1 antibodies and cut-offs to determine
positivity141. In a phase 1 study of nivolumab in patients with
advanced melanoma, there were no responses in 17 patients
with PD-L1 negative tumors in comparison to 9 responses
out of 25 (36%) with PD-L1 positive tumors (P=0.006)142.
Subsequent studies in melanoma patients have however been
variable,  with  some  showing  a  positive  correlation  with
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tumor  PD-L1  expression  and  others  not137,143,144.  For
NSCLC,  PD-L1  expression  appears  to  correlate  more
consistently  with  response  to  anti-PD-1/PD-L1  antibody
treatments across studies33,145, however, in all tumor types, a
healthy response rate to anti-PD-1/PD-L1 therapies is still
seen  in  PD-L1  negative  tumors.  Such  an  observation  is
probably not unexpected since there is growing evidence that
PD-L1  express ion  changes  over  t ime  and  wi th
treatment146,147. It is thus possible that single measurements
of PD-L1 expression from archival tumor biopsies may not
be  sufficiently  representative  of  metastatic  disease.
Interestingly, as mentioned earlier in this review, in a recent
phase 3 study in previously untreated patients with metastatic
melanoma, tumors negative for PD-L1 expression had a PFS
benefit from the combination of anti-CTLA4 and anti-PD-1
treatment compared to either treatment alone35. By contrast,
the combination of nivolumab and ipilimumab showed no
PFS benefit compared to nivolumab alone in patients with
PD-L1 positive tumors suggesting that only those tumors
l a c k i n g  P D - L 1  e x p r e s s i o n  m i g h t  b e n e f i t  f r o m
immunotherapy  combination  approaches.  Currently
therefore,  PD-L1  expression  in  archival  tumor  samples
should  not  be  used  to  exclude  patients  from anti-PD-L1
treatments and further work is required to fully understand
the usefulness of PD-L1 expression as a biomarker predicting
clinical response to anti-PD-1/PD-L1 treatments148,149.
The presence of melanoma antigen-directed activated T
cells is prognostic for the improved survival of melanoma
patients  and upregulation of  such tumor-targeting T cell
subsets  correlates  with  clinical  benefit  to  anti-CTLA4
antibody treatment150,151. Despite this however, attempts to
focus  the  immune  system  towards  specific  antitumor
antigens  using  vaccines  in  combination with  ipilimumab
have failed to show any additional benefit over ipilimumab
alone,  questioning  the  robustness  of  these  approaches  as
predictive biomarkers of response139,152. Nevertheless, it is
now recognized that  tumors  with a  high mutational  load
generate increased levels of neo-antigens, and specific neo-
antigen  signatures  have  been  shown  to  correlate  with
antitumor responses to anti-CTLA4 treatments153.
Similarly, a higher non-synonymous mutation burden in
NSCLC  tumors  was  associated  with  improved  objective
response, durable clinical benefit, and PFS after treatment
with pembrolizumab154.  In  keeping with this,  CRCs with
MMR  deficiencies  demonstrated  significant  antitumor
responses and survival  benefits  following pembrolizumab
treatment  compared  to  MMR  proficient  tumors37 .
Combining cytotoxic chemotherapy with immunotherapy
aims to increase tumor antigen presentation and it will be
interesting  to  see  if  measuring  levels  of  activated  T  cell
subsets or neo-antigens will predict for clinical benefit in this
setting.
Another approach will be to characterize the composition
of  the  immune  infiltrate  in  the  tumor  before  and  after
treatment.  In mice,  tumor depletion of  regulatory T cells
following antibody treatment against OX40 correlates with
tumor regression, therefore Treg depletion or reduction of
Treg dependent cytokines such as IL-10, are both potential
biomarker  options  for  predicting clinical  benefit155,156.  A
recent study has suggested that pre-existing CD8 expression
at the invasive margin of  tumors may be a biomarker for
tumors  with  adaptive  immune  resistance  and  might  also
therefore  predict  response  to  PD-1  inhibitors157.  Fresh
invasive tumor biopsies are unlikely to be practical outside a
research setting, however recent advances in the ability to
non-invasively image inflammatory responses using positron
emission  tomography  (PET)  may  enable  the  dynamic
monitoring  of  immune  reactivation  in  tumors  following
treatment158.
Monitoring of toxicities in early
phase clinical trials
Close monitoring and early recognition of immunotherapy
toxicities as well as effective management with established
protocols  and  standard  operating  procedures  are  critical
when  testing  new  immunotherapy  combinations.  For
example,  toxicities  associated  with  immune  checkpoint
inhibitors  are  widely  different  in  their  underlying
mechanisms  involved,  clinical  features  and  necessary
treatments,  in  contrast  to  conventional  cytotoxic
chemotherapies. In addition, as new combination regimens
are developed, it is entirely possible that new or unexpected
toxicities will arise.
As  we  continue  to  build  exponentially  on  the  use  of
different immunotherapies, it is likely that our experience in
recognizing and managing immune-related toxicities will no
doubt  improve.  It  is  important  to  recognize  that  such
immune-related  adverse  events  range  from  mild  to  life
threatening, with inflammatory colitis being responsible for
the majority of immunotherapy-related deaths. To illustrate
this point, irAEs may occur in up to 62% of patients treated
with  ipilimumab  and  involve  the  skin  (rash,  pruritus),
gastrointestinal tract (diarrhea, colitis), liver (hepatitis) and
endocrine system (hypothyroidism, hypopituitarism, adrenal
insufficiency, hypophysitis), with grade 3 or 4 adverse events
occurring in up to 20% of patients26,34. Rarely, neurological
toxicity can also occur and cases of transverse myelitis and
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Guillain-Barre syndrome have both been described159. The
spectrum  of  toxicities  associated  with  anti-PD-1/PD-L1
antibodies  is  similar  to  anti-CTLA  treatments,  although
toxicity  generally  occurs  less  frequently  and  is  often  less
severe, with grade 3-4 AEs occurring in approximately 10%
of patients34. Treatment-related pneumonitis is perhaps the
exception, which has been described more commonly with
anti-PD-L1/PD-1  therapies  compared  to  anti-CTLA
antibodies and is a potential concern with anti-PD-1/PD-L1
combination studies.
Whilst  concurrent  targeting of  CTLA and PD-1/PD-L1
significantly improves response rates in the melanoma clinic,
the incidence of grade 3-4 toxicities are more than doubles
(55% for combination vs.  27% for ipilimumab alone) and
36%-45% of patients discontinue combination treatment due
to toxicity, most commonly diarrhea or colitis35,144.  Up to
90% of patients receiving nivolumab in combination with
ipilimumab  require  some  form  of  immunosuppressive
treatment, although in >80% patients, grade 3-4 immune-
related  adverse  events  do  resolve  completely35,144.  The
combination of  ipilimumab with  other  anti-PD-1/PD-L1
antibodies also appears to result in similar toxicity profiles90.
Combination studies of anti-PD-1/PD-L1 antibodies with
cytotoxic chemotherapy have yielded impressive response
rates,  with  associated  high  rates  of  adverse  events27,48.
Pneumonitis in particular appears to occur more frequently
when anti-PD-1/PD-L1 antibodies are used in combination
with either chemotherapies or molecularly targeted agents48.
Establishing  the  maximum  tolerated  dose  (MTD)  is  a
traditional  phase  1  trial  endpoint  and  is  often  used  to
determine the recommended phase 2 dose. Whilst the MTD
is  valid  for  cytotoxic  treatments  in  view  of  their  dose-
dependent toxicities, its usefulness in immunotherapy trials
remains controversial. Although the frequency and severity
of immune-related toxicities appears to be dose-dependent
for anti-CTLA4 antibodies such as ipilimumab, there does
not appear to be such a correlation between dose and toxicity
f o r  a n t i - P D - 1 / P D - L 1  a n t i b o d i e s  s u c h  a s
pembrolizumab47,160. These differences may reflect the varied
underlying mechanisms of action underpinning anti-CTLA4
versus anti-PD-1/PD-L1 antibodies, and also question the
use  of  the  MTD  as  a  primary  endpoint  in  early  phase
1mmunotherapy  monotherapy  and  combination  trials.
Novel,  adaptive phase 1 trial  designs that incorporate the
establishment of an optimum biological dose (OBD) range
have been implemented successfully, however an OBD range
will  ultimately  be  challenging  to  define  with  novel
immunotherapies,  unless  a  robust,  biologically-relevant,
pharmacodynamic (PD) biomarker exists161.
Currently,  the  severity  and  timing  of  conventional
definitions  for  DLTs  are  pre-defined  in  trial  protocols.
However,  DLTs for  immunotherapy trials  clearly  need to
incorporate irAEs and differentiate between those that are
quickly reversible or treatable (such as skin toxicity or single-
organ endocrine disorders) versus those that are potentially
life-threatening  if  treatment  is  not  withdrawn  (such  as
colitis). DLTs are traditionally defined as occurring within
the first  treatment cycle (often 3-4 weeks),  however most
irAEs  are  known  to  occur  outside  this  window,  peaking
around 6-8 weeks and are often slow to resolve. Such factors
need to be considered when defining immunotherapy trial-
specific  DLT  periods  and  criteria162.  The  design  of
combination  studies  involving  immunotherapies  and
conventional  cytotoxic  chemotherapy will  be  particularly
challenging  and  may  require  different  DLT  windows
depending on the nature of the AE.
Another  important  consideration is  that  for  both anti-
CTLA4  and  PD-1/PD-L1  inhibitors,  autoimmunity  may
correlate with clinical response. For example, two-thirds of
patients who discontinued nivolumab/ipilimumab treatment
due to toxicity went on achieve an objective response144,163. If
the presence of irAEs correlates with response, trial protocols
need to establish clear guidelines for the management of such
toxicities,  which  should  not  necessarily  result  in  patient
withdrawal from study.
Finally,  whilst  OS  is  not  usually  a  primary  outcome
measure for phase 1 studies, the growing trend to combine
phase  1  and  2  studies  during  clinical  drug  development
means  statistical  consideration  of  such  outcomes  is
i m p o r t a n t  e a r l y  o n .  T o  d a t e ,  O S  b e n e f i t s  f o r
immunotherapies have been demonstrated in a minority, but
are  generally  substantial  for  those  who  do  respond,  as
demonstrated by the 'long tail' on the Kaplan-Meier survival
curve.  This  unique  response  pattern  results  in  delayed
separation of Kaplan-Meier survival curves, which if analyzed
using standard statistical methods, may fail to demonstrate a
statistically significant OS benefit164,165. Use of randomised
phase 2 studies, helps to identify occasions when the above
may occur and when utilized, will better guide the statistical
design of subsequent phase 3 studies.
In the future, with increased experience and knowledge of
the toxicity profiles associated with immunotherapy drugs,
both  as  single  agents  and  in  combination  with  other
therapeutics, we should be able to prospectively optimize and
adapt  combination trial  designs.  However,  at  the current
time,  for  new  immunotherapy  combination  trials  being
conducted, careful consideration and monitoring of dose,
schedule, clinical outcomes and trial parameters will require
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thoughtful  flexibility  and  adaptation  to  ensure  the  best
outcomes for both patients and the study compound.
Assessing antitumor responses in
immunotherapy combination trials
Upon the observation of objective clinical and radiological
responses  with  immunotherapies  in  early  phase  trials,  it
became clear  that  unique kinetics  and patterns of  disease
response occurred in contrast to other anticancer treatments.
It  was recognized that tumor infiltration of immune cells
could  result  in  a  period  of  apparent  or  “pseudo”  tumor
growth prior to delayed tumor shrinkage. In addition, the
initial immune-cell infiltration into previously unidentified
malignant lesions could be falsely interpreted as progressive
disease using standard response evaluation criteria in solid
tumors (RECIST). Consequently, immune-related response
criteria  were  defined  to  address  these  unique  clinical
scenarios166.
The immune-related RECIST criteria have been modified
to be more in line with RECIST 1.1 and now incorporate the
use of uni-dimensional measurements and a reduced number
of  target  lesions167,168.  Assessing  disease  response  during
immunotherapy  combination  studies  will  be  particularly
challenging  as  the  phenotypes  and  kinetics  of  tumor
responses  may  alter  once  again.  This  is  a  complex  and
dynamic area, and ultimately both the timing and criteria for
response assessments will require thoughtful consideration so
as to avoid both premature treatment cessation of effective
combinations,  as  well  as  the  persistence  of  treatment  in
patients  deriving  no  clinical  benefit.  Such strategies  may
require the personalization of  radiological  assessments to
each  combination  regimen  and  perhaps  even  the
individualization of such criteria and imaging modality to
each  patient.  For  example,  with  immuno-oncology
combinations,  it  will  be  important  to  establish  a  priori
specific trial criteria for treatment discontinuation, which
may  incorporate  standard  or  immune-related  RECIST
criteria, depending on the partner drugs involved.
Increased efforts should also focus on the development of
novel functional and molecular imaging techniques to assess
the micro-structural properties of tumors in order to provide
an early surrogate biomarker of treatment-related changes,
rather than size-based parameters. Examples of such modern
imaging  modalities  include  novel  PET  and  functional
magnetic resonance techniques.
Conclusions
Immunotherapy is a rapidly evolving and complex field that
offers great potential to deliver substantial benefits to patients
with  a  range  of  different  cancers.  A number  of  approved
therapies already exist that offer impressive and long lasting
responses in some patients. It is now clear however that a
substantial  proportion of  patients  do  not  respond to  the
immunotherapies currently available. Better patient selection
through the use of  more precise predictive biomarkers of
response  may  potentially  help;  however,  no  clinically
validated robust  biomarkers currently exist.  As such,  it  is
highly likely that combination therapies will be required to
increase  responses  to  immunotherapy.  Already,  the
combination  of  nivolumab  and  ipilimumab  through  the
targeting of different but complimentary pathways has been
shown to substantially increase response rates and PFS in
metastatic melanoma. Long term data is awaited to confirm
that  responses  are  truly  durable  and  that  the  tail  of  the
survival curve has been raised as with ipilimumab. However
this combination and many other combinations discussed
herein hold much promise in delivering this outcome. The
improvements in outcomes do however come at the cost of
increased drug-related toxicities. As already discussed in this
review,  multiple  other  combination  therapies  hold  great
promise  to  increase  the  immunogenicity  of  tumors  and
thereby  improve  outcomes  in  patients  who  would  not
necessar i ly  benef i t  f rom  s ingle  agent  treatment .
Chemotherapy, radiotherapy and targeted therapies all hold
genuine  promise  as  potential  partners  with  different
immunotherapeutic agents. Caution of course still needs to
be applied since combination therapies always bear the risk
of leading to synergistic toxicities. The use of anti-PD-1/PD-
L1 agents as the immunotherapy backbone rather than anti-
CTLA4 antibodies  may  potentially  mitigate  combination
toxicities to some degree.
It  is  critical  for  the  design  of  immunotherapy-based
combination clinical trials to be based on strong preclinical
rationale  coupled  with  a  thorough  understanding  of
established scientific principles. Although there is much hope
for  chemotherapy  or  molecularly  targeted  therapies  to
increase tumor immunogenicity, there is still great potential
that exists for some treatments to be immunosuppressive and
as such, negate the potential benefit of the immunotherapy
involved. Many combinations are currently still in preclinical
or  early  phase  trial  development.  Most  if  not  all  of  these
combinations require meticulous clinical trial testing initially
in phase 1 trials to confirm their safety profiles, but also to
assess for preliminary signals of antitumor activity. Such trial
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designs will need to incorporate any preclinical and clinical
data  on the  unique  toxicity  profiles  in  question,  so  as  to
inform the starting doses of both drugs and the subsequent
dosing  and  scheduling  of  the  combination.  Of  course,
significant chronic toxicities may develop beyond the first
cycle  of  treatment,  and  such  factors  will  need  to  be
considered when evaluating the overall safety profile of the
novel combination. But likewise,  the potential  for certain
toxicities to predict antitumor response will need to taken
into  account,  for  example  the  higher  rate  of  response  in
patients who experienced grade 3/4 irAE when treated with
combination ipilimumab and nivolumab35. Trial designs will
also  need  to  consider  different  endpoints  of  drug
effectiveness such as durable control rates. Although RECIST
response rates will remain important, the meaningful benefit
of  immunotherapy has  thus  far  been with the  impressive
durable survival  rates,  and the elevation of  the tail  of  the
survival curve. As such, capturing this metric and developing
valid  predictive  biomarkers  for  this  endpoint  will  be
important in future trials. Phase 1 trials will also need to be
designed to learn as  much about  the  combinations  being
tested through detailed pharmacokinetic testing for drug-
drug interactions and if possible, tumor biopsies to confirm
putative  mechanisms  of  action  and  to  assess  putative
predictive biomarkers of response.
Much  has  now  been  established  about  the  immune
response  to  tumors  and  the  associated  mechanisms  of
immune escape. However, we are clearly still at the tip of the
iceberg  with  regards  to  exploit ing  such  targeted
immunological  strategies.  Hypothesis-testing,  biomarker-
driven early phase clinical  trials  are ideally placed to help
improve our burgeoning knowledge of the complex biology
involved with such treatments through the testing of novel
immunotherapy-based combination regimens in advanced
cancer patients. It is only through such strategies that we will
finally be able to fulfil the promise that such new treatments
bring to the advancement of modern oncology.
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